OCULUS joins International Myopia Institute in mission to raise myopia awareness


OCULUS has combined efforts with International Myopia Institute to raise awareness of myopia and drive scientific advancements to prevent sight-threatening complications and blindness, which may arise as a result.

OCULUS joins International Myopia Institute in mission to raise myopia awareness

OCULUS has joined forces with the International Myopia Institute (IMI) to raise awareness of myopia and will support research activities to prevent future vision impairment and loss.

“We are delighted about the cooperation,” said Christian Kirchhübel, CEO of OCULUS. “Our mission at OCULUS is to support eye care professionals around the world with cutting-edge, high-tech development. We are dedicated to saving and improving vision and visual performance with our precise, reliable long-lasting measurement solutions.”


OCULUS is an ophthalmic device company, providing sophisticated technology to meet the daily challenges that eye care professionals encounter. It was established in 1895 as a family business and continues to be managed by third and fourth generations. All devices are designed and manufactured at the OCULUS headquarters in Wetzlar, Germany, and there are 12 subsidiaries in Europe, Asia and America.

International Myopia Institute

The International Myopia Institute was formed in 2015 to address the increasing levels of myopia and high myopia, which may lead to sight-threatening complications. The group of global experts aim to advance research, patient management, and education in myopia to prevent future vision impairment and blindness associated with nearsightedness. Made up of scientists, clinicians, policy makers, government officials, and educators, the IMI create white papers and clinical summaries and make them available worldwide in a variety of languages.

“We are thrilled to have OCULUS join in our mission to advance research, patient management and education in myopia,” said Dr Monica Jong, IMI Executive Director. “Open collaboration and sharing of knowledge globally with eye care practitioners (ECPs) are critical to prevent future myopia-related vision impairment and blindness. We will continue to bring the latest, evidence-based information directly to ECPs across the world which would not be possible without our industry supporters.”

Related Content: Cataract & Refractive | Inflammation & Infection | Paediatrics

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.